CR7285A - A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES - Google Patents

A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES

Info

Publication number
CR7285A
CR7285A CR7285A CR7285A CR7285A CR 7285 A CR7285 A CR 7285A CR 7285 A CR7285 A CR 7285A CR 7285 A CR7285 A CR 7285A CR 7285 A CR7285 A CR 7285A
Authority
CR
Costa Rica
Prior art keywords
procedure
reduce mortality
critical diseases
morbility
diseases
Prior art date
Application number
CR7285A
Other languages
Spanish (es)
Inventor
Efendic Suad
Anthony Jakubowski Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to CR7285A priority Critical patent/CR7285A/en
Publication of CR7285A publication Critical patent/CR7285A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion describe el uso de compuestos peptidicos del tipo glucagon (GLP-1) para reducir la mortalidad y morbilidad asociada a enfermedades criticas donde el paciente esta peredispuesto a/o sufre algun tipo de insuficiencia respiratoria.The present invention describes the use of glucagon peptide compounds (GLP-1) to reduce mortality and morbidity associated with critical diseases where the patient is subject to / or suffers from some type of respiratory failure.

CR7285A 2004-03-15 2004-03-15 A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES CR7285A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CR7285A CR7285A (en) 2004-03-15 2004-03-15 A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CR7285A CR7285A (en) 2004-03-15 2004-03-15 A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES

Publications (1)

Publication Number Publication Date
CR7285A true CR7285A (en) 2004-05-11

Family

ID=44839171

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7285A CR7285A (en) 2004-03-15 2004-03-15 A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES

Country Status (1)

Country Link
CR (1) CR7285A (en)

Similar Documents

Publication Publication Date Title
ECSP045044A (en) A PROCEDURE TO REDUCE MORTALITY AND MORBILITY ASSOCIATED WITH CRITICAL DISEASES
CL2011003173A1 (en) Glucagon analog, gip and glp-1 agonist; dimer comprising the glucagon analog; conjugated to the analog; composition comprising said analog; use to prepare a medicine to treat diabetes, reduce weight gain, or induce weight loss.
AR053495A1 (en) PEPTIDE MODULATORS 1 SIMILAR TO HUMAN GLUCAGON AND ITS USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
CL2012003053A1 (en) Pharmaceutical combination comprising a glp-1 receptor agonist and linagliptin, dpp-4 inhibitor; use of the pharmaceutical combination for the treatment of type 2 diabetes and obesity.
AR061242A1 (en) STABILIZED INSULIN TYPE GROWTH FACTOR POLYPEPTIDES
Duncan et al. Mi vida
CL2017001760A1 (en) Co-agonist compounds of gip and glp-1
ECSP034811A (en) DERETADOS HETEROCICLILOXI-, -TIOXI - Y - AMINOBENZAZOLE SUCH AS LIGANDOS 5-HIDROXITRIPTAMINA-6
ECSP21030933A (en) PROTEIN TYROSINE-TYROSINE ANALOGUES AND METHODS OF USE OF IT
CL2012003641A1 (en) Analog glucagon compound comprising substitutions of amino acid residues in positions 3 and / or 4 of the native glucagon and having activity in the glucagon receptor and / or the glp-1 receptor; pharmaceutical composition comprising the compound; use of the compound to prevent weight gain or promote weight loss in a subject in need.
UY28757A1 (en) SUBSTITUTED PIRAZOLINE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
ECSP045474A (en) 1- (AMINOALQUIL) -3-SULPHONYLAZAINDOLS AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS
ECSP12012181A (en) NEW PEPTIDES AND METHODS FOR PREPARATION AND USE
ECSP099079A (en) PEPTIDE MIMETICBODIES-1 SIMILAR TO HUMAN GLUCAGON, COMPOSITIONS, METHODS AND USES
AR061203A1 (en) GLP-1 RECEIVER MODULATORS MODIFIED IN TERMINAL N
AR054426A1 (en) USE OF AN INHIBITOR OF THE DYMERIZATION OF THEROSINE KINASE RECEIVERS HER FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO EXTEND THE TIME UNTIL THE PROGRESSION OF THE DISEASE OR SURVIVAL OF CANCER PATIENTS
PE20100056A1 (en) GLUCAGON ANALOGS AS GIP AGONISTS
PT2322546E (en) GLP-1 COMPOSED ACILADOS
SV2008002855A (en) MILNACIPRAN FOR THE LONG-TERM TREATMENT OF THE FIBROMIALGIA SYNDROME
PA8564001A1 (en) AZA-ARILPIPERAZINAS
GT200300142A (en) RECEIVER AGONISTS (VPAC2) OF THE ACTIVATING PEPTIDE OF THE HYPOFISARY CYCLASS ADENYLATE (PACAP) AND ITS PHARMACOLOGICAL USE METHODS
UY28080A1 (en) POSITIONAL ISOMERS OF IFN PEG ALFA 2A
CL2015002914A1 (en) Treatment of diabetes mellitus through long-acting insulin formulations
AR057239A1 (en) IMMUNOGLOBULINS
ES2525009T3 (en) Glycoproteins that have lipid mobilization properties and therapeutic uses thereof